209256-69-9

Usage

Uses

Used in Pharmaceutical Industry:
(2E)-3-(2,3-dihydro-1-benzofuran-4-yl)prop-2-enoic acid is used as a potential medicinal compound for its possible biological activity. Its unique chemical structure, including the benzofuran ring, may contribute to its potential therapeutic effects.
Used in Biochemistry:
(2E)-3-(2,3-dihydro-1-benzofuran-4-yl)prop-2-enoic acid may be utilized in biochemical research to study its interactions with biological systems and to explore its potential as a bioactive molecule.
Used in Organic Synthesis:
(2E)-3-(2,3-dihydro-1-benzofuran-4-yl)prop-2-enoic acid can be used as a building block or intermediate in the synthesis of more complex organic molecules, potentially leading to the development of new pharmaceuticals or other organic compounds with specific applications.

Upstream product

• 141-82-2 malonic acid 
• 209256-42-8 2,3-dihydro-1-benzofuran-4-carbaldehyde 
• 123-75-1 pyrrolidine 

Downstream Products

• 209257-15-8 (-)-(trans)-2-(2,3-dihydrobenzofuran-4-yl)cyclopropanemethanamine 
• 609799-22-6 [14C]-Tasimelteon 
• 209257-15-8 1-[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methanamine 

Relevant academic research and scientific papers

CYCLOPROPYL DIHYDROBENZOFURAN MODULATORS OF MELATONIN RECEPTORS

The present invention relates to new cyclopropyl dihydrobenzofuran modulators of melatonin receptors, pharmaceutical compositions thereof, and methods of use thereof.

ACYL GUANIDINE SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD

Acyl guanidines are provided which are sodium/proton exchange (NHE) inhibitors which have the structure wherein n is 1 to 5; X is N or C-R5 wherein R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; and R1, R2, R3 and R4 are as defined herein, and where X is N, R1 is preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above acyl guanidines.

Acyl guanidine sodium/proton exchange inhibitors and method

Acyl guanidines are provided which are sodium/proton exchange (NHE) inhibitors which have the structure STR1 wherein n is 1 to 5; X is N or C--R5 wherein R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; and R1, R2, R3 and R4 are as defined herein, and where X is N, R1 is preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above acyl guanidines.